• Memory Pharmaceuticals Corp., of Montvale, N.J., said it completed a Phase I multiple-ascending dose study of R4996/MEM 63908 in healthy volunteers and expects to report top-line results from the entire Phase I program in the fourth quarter. The drug, a partial agonist of the nicotinic alpha-7 receptor, is partnered with Basel, Switzerland-based F. Hoffmann-La Roche Ltd.

• Thallion Pharmaceuticals Inc., of Montreal, said it enrolled the first patient in its Phase II trial of TLN-4601 as a second-line monotherapy treatment for glioblastoma multiforme. The study will enroll up to 40 patients to receive TLN4601, administered continuously intravenously over 21-day cycles (14 days on and seven days off). The primary endpoint is six-month progression-free survival, and secondary endpoints include tumor response, progression-free survival at 12 months and overall survival. Thallion also was cleared by the FDA to proceed with the U.S. portion of that trial following submission of its investigational new drug application.